These are the 10 most heavily shorted stocks in the market right now
Seeking Alpha News (Wed, 13-May 12:27 PM ET)
Hims & Hers breaks further below key technical level after earnings miss
Seeking Alpha News (Wed, 13-May 11:02 AM ET)
Hims & Hers Earnings Call Balances Pain With Growth
TipRanks (Tue, 12-May 8:21 PM ET)
‘An Attractive Opportunity,’ Says Top Investor About Hims & Hers Stock
TipRanks (Tue, 12-May 4:03 PM ET)
Hims & Hers winning bullish views despite Q1 miss
Seeking Alpha News (Tue, 12-May 1:41 PM ET)
Morning News Wrap-Up, 5/12/26: Today’s Biggest Stock Market Stories!
TipRanks (Tue, 12-May 12:53 PM ET)
Biggest stock movers Tuesday: PLUG, HIMS, ASTS, QUBT, and more
Seeking Alpha News (Tue, 12-May 11:30 AM ET)
TipRanks (Tue, 12-May 10:50 AM ET)
Evercore ISI Sticks to Its Hold Rating for Hims & Hers Health (HIMS)
TipRanks (Tue, 12-May 10:36 AM ET)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Globe Newswire (Tue, 12-May 9:00 AM ET)
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health Class A trades on the NYSE stock market under the symbol HIMS.
As of May 13, 2026, HIMS stock price declined to $24.14 with 23,575,609 million shares trading.
HIMS has a beta of 1.56, meaning it tends to be more sensitive to market movements. HIMS has a correlation of 0.04 to the broad based SPY ETF.
HIMS has a market cap of $5.59 billion. This is considered a Mid Cap stock.
Last quarter Hims & Hers Health Class A reported $608 million in Revenue and -$.40 earnings per share. This fell short of revenue expectation by $-9 million and missed earnings estimates by -$.44.
In the last 3 years, HIMS traded as high as $72.98 and as low as $5.65.
The top ETF exchange traded funds that HIMS belongs to (by Net Assets): IJH, VTI, IWM, VB, VBK.
HIMS has underperformed the market in the last year with a price return of -56.3% while the SPY ETF gained +28.6%. However, in the short term, HIMS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +52.8% vs +9.2% return in SPY. But in the last 2 weeks, HIMS shares have been beat by the market, returning -13.5% compared to an SPY return of +4.3%.
HIMS support price is $23.49 and resistance is $26.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIMS shares will trade within this expected range on the day.